The metabolism of glucocerebrosides — From 1965 to the present

Molecular Genetics and Metabolism

Volumn 120, Issue 1-2, 2017, Pages 22-26

  Futerman, Anthony H ^a   Platt, Frances M ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Enzyme replacement therapy; Gaucher disease; Glucosylceramide; Substrate reduction therapy

Indexed keywords

GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE;

BIOCHEMISTRY; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); GAUCHER DISEASE; HUMAN; LIPID DEGRADATION; LIPOGENESIS; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPHINGOLIPID METABOLISM; CHEMISTRY; ENZYME REPLACEMENT; GENETICS; HISTORY; METABOLISM; MUTATION; PROCEDURES; PROTEIN TERTIARY STRUCTURE;

ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY;

EID: 85007575179     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2016.11.390     Document Type: Review

References (40)

1. [1] De Duve, C., Exploring cells with a centrifuge. Science 189 (1975), 186–194.
2. [2] Brady, R.O., KANFER, J., Shapiro, D., The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J. Biol. Chem. 240 (1965), 39–43.
3. [3] Brady, R.O., Kanfer, J.N., Shapiro, D., Metabolism of glucocerebrosides II: evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 18 (1965), 221–225.
4. [4] Brady, R.O., Kanfer, J.N., Bradley, R.M., Shapiro, D., Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45 (1965), 1112–1115, 10.1172/JCI105417.
5. [5] Stone, D.L., Tayebi, N., Orvisky, E., Stubblefield, B., Madike, V., Sidransky, E., Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum. Mutat. 15 (2000), 181–188, 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S.
6. [6] Futerman, A.H., Sussman, J.L., Horowitz, M., Silman, I., Zimran, A., New directions in the treatment of Gaucher disease. Trends Pharmacol. Sci. 25 (2004), 147–151, 10.1016/j.tips.2004.01.004.
7. [7] Dvir, H., Harel, M., McCarthy, A.A., Toker, L., Silman, I., Futerman, A.H., et al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4 (2003), 704–709, 10.1038/sj.embor.embor873.
8. [8] Futerman, A.H., Zimran, A., (eds.) Gaucher Disease, 2006, CRC Press, Taylor and Francis Group, Boca Raton, FL.
9. [9] Liou, B., Grabowski, G.A., Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease. Mol. Genet. Metab. 97 (2009), 65–74, 10.1016/j.ymgme.2009.01.006.
10. [10] Liou, B., Analyses of variant acid beta-Glucosidases: effects of Gaucher disease mutations. J. Biol. Chem. 281 (2006), 4242–4253, 10.1074/jbc.M511110200.
11. [11] Brumshtein, B., Greenblatt, H.M., Butters, T.D., Shaaltiel, Y., Aviezer, D., Silman, I., et al. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J. Biol. Chem. 282 (2007), 29052–29058, 10.1074/jbc.M705005200.
12. [12] Wei, R.R., Hughes, H., Boucher, S., Bird, J.J., Guziewicz, N., Van Patten, S.M., et al. X-ray and biochemical analysis of N370S mutant human acid-glucosidase. J. Biol. Chem. 286 (2010), 299–308, 10.1074/jbc.M110.150433.
13. [13] Offman, M.N., Krol, M., Silman, I., Sussman, J.L., Futerman, A.H., Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S. J. Biol. Chem. 285 (2010), 42105–42114, 10.1074/jbc.M110.172098.
14. [14] Offman, M.N., Krol, M., Rost, B., Silman, I., Sussman, J.L., Futerman, A.H., Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease. Protein Eng. Des. Sel. 24 (2011), 773–775, 10.1093/protein/gzr032.
15. [15] Vitner, E.B., Vardi, A., Cox, T.M., Futerman, A.H., Emerging therapeutic targets for Gaucher disease. Expert Opin. Ther. Targets, 000–000, 2014, 10.1517/14728222.2014.981530.
16. [16] Reczek, D., Schwake, M., Schröder, J., Hughes, H., Blanz, J., Jin, X., et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase. Cell 131 (2007), 770–783, 10.1016/j.cell.2007.10.018.
17. [17] Brumshtein, B., Salinas, P., Peterson, B., Chan, V., Silman, I., Sussman, J.L., et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20 (2010), 24–32, 10.1093/glycob/cwp138.
18. [18] Zimran, A., Brill-Almon, E., Chertkoff, R., Petakov, M., Blanco-Favela, F., Munoz, E.T., et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118 (2011), 5767–5773, 10.1182/blood-2011-07-366955.
19. [19] Shaaltiel, Y., Bartfeld, D., Hashmueli, S., Baum, G., Brill-Almon, E., Galili, G., et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 5 (2007), 579–590, 10.1111/j.1467-7652.2007.00263.x.
20. [20] Platt, F.M., Sphingolipid lysosomal storage disorders. Nature 510 (2014), 68–75, 10.1038/nature13476.
21. [21] Basu, S., Kaufman, B., Roseman, S., Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain. J. Biol. Chem. 243 (1968), 5802–5804.
22. [22] Futerman, A.H., Pagano, R.E., Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. Biochem. J. 280:Pt 2 (1991), 295–302.
23. [23] Radin, N.S., Vunnam, R.R., Inhibitors of cerebroside metabolism. Methods Enzymol. 72 (1981), 673–684.
24. [24] Radin, N.S., Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 13 (1996), 153–157.
25. [25] Abe, A., Radin, N.S., Shayman, J.A., Wotring, L.L., Zipkin, R.E., Sivakumar, R., et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 36 (1995), 611–621.
26. [26] Platt, F.M., Reinkensmeier, G., Dwek, R.A., Butters, T.D., Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J. Biol. Chem. 272 (1997), 19365–19372.
27. [27] Lachmann, R.H., Miglustat. Oxford GlycoSciences/Actelion. Curr. Opin. Investig. Drugs 4 (2003), 472–479.
28. [28] Platt, F.M., Neises, G.R., Dwek, R.A., Butters, T.D., N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269 (1994), 8362–8365.
29. [29] Ridley, C.M., Thur, K.E., Shanahan, J., Thillaiappan, N.B., Shen, A., Uhl, K., et al. Beta-glucosidase 2 (GBA2) activity and imino sugar pharmacology. J. Biol. Chem., 2013, 10.1074/jbc.M113.463562.
30. 3. J. Acquir. Immune Defic. Syndr. 7 (1994), 139–147.
31. [31] Cox, T., Lachmann, R., Hollak, C., Aerts, J., Van Weely, S., Hrebicek, M., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355 (2000), 1481–1485.
32. [32] Abian, O., Alfonso, P., Velazquez-Campoy, A., Giraldo, P., Pocovi, M., Sancho, J., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol. Pharm. 8 (2011), 2390–2397, 10.1021/mp200313e.
33. [33] Andersson, U., Butters, T.D., Dwek, R.A., Platt, F.M., N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59 (2000), 821–829.
34. [34] Shen, C., Bullens, D., Kasran, A., Maerten, P., Boon, L., Aerts, J.M.F.G., et al. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. Int. Immunopharmacol. 4 (2004), 939–951, 10.1016/j.intimp.2004.04.008.
35. [35] Shayman, J.A., ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35 (2010), 613–620.
36. [36] P.T.M.C. F MedSci, G.D. MD, R.C. MD, M.B. MD, T.A.B. MD, A.M.M. MD, et al. ArticlesEliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet, 1–8, 2015, 10.1016/S0140-6736(14)61841-9.
37. [37] Belmatoug, N., di Rocco, M., Fraga, C., Giraldo, P., Hughes, D., Lukina, E., et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. 2016, Eur. J. Intern. Med., 10.1016/j.ejim.2016.07.011.
38. [38] Smid, B.E., Ferraz, M.J., Verhoek, M., Mirzaian, M., Wisse, P., Overkleeft, H.S., et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J. Rare Dis., 11, 2016, 28, 10.1186/s13023-016-0413-3.
39. [39] Wraith, J.E., Vecchio, D., Jacklin, E., Abel, L., Chadha-Boreham, H., Luzy, C., et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol. Genet. Metab. 99 (2010), 351–357, 10.1016/j.ymgme.2009.12.006.
40. [40] Celastrol Increases Glucocerebrosidase Activity in Gaucher Disease by Modulating Molecular Chaperones. 2013, 1–6, 10.1073/pnas.1321341111/-/DCSupplemental.